Jeff Kent Biography and Net Worth

Dr. Jeffrey D. Kent joined Horizon in May 2012. Before joining Horizon, Dr. Kent was executive director, medical affairs at Astellas Pharmaceuticals. Before Astellas, he spent over eight years as global project head for medical affairs in immunology within Abbott Global Pharmaceutical research and development. In this capacity, he had global medical affairs responsibility for HUMIRA across the rheumatology, dermatology and gastroenterology therapeutic areas. Dr. Kent also worked at Searle (now Pfizer) from 1999 to 2003 and served in various capacities in research and development including global director for valdecoxib (Bextra) development.

Dr. Kent is a graduate of Franklin and Marshall College and the Jefferson Medical College in Philadelphia where he received his medical degree. He completed a residency in internal medicine at Thomas Jefferson University Hospital and a fellowship in gastroenterology and hepatology at Rush Presbyterian St. Luke's Hospital in Chicago. He served as a full-time faculty member for several years in the Department of Internal Medicine and the Division of Digestive Diseases at Rush Medical College and Rush Presbyterian St. Luke's Hospital. While at Rush, Dr. Kent was heavily involved with clinical practice, educating medical students, residents and fellows, and developed extensive experience with Phase 2-4 clinical trials. Following his experience at Rush, he served as Associate Medical Director for the Evanston Hospital Clinical Pharmacology Unit, a Phase 1 clinical trials facility and gained experience with first-in-man and ADME studies.

What is Jeff Kent's net worth?: The estimated net worth of Jeff Kent is at least $8.35 million as of November 5th, 2020. Kent owns 71,799 shares of Horizon Therapeutics Public stock worth more than $8,350,224 as of November 15th. This net worth estimate does not reflect any other assets that Kent may own. Learn More about Jeff Kent's net worth.
How do I contact Jeff Kent?: The corporate mailing address for Kent and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Jeff Kent's contact information.
Has Jeff Kent been buying or selling shares of Horizon Therapeutics Public?: Jeff Kent has not been actively trading shares of Horizon Therapeutics Public during the last ninety days. Most recently, Jeff Kent sold 47,944 shares of the business's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $78.94, for a transaction totalling $3,784,699.36. Following the completion of the sale, the insider now directly owns 71,799 shares of the company's stock, valued at $5,667,813.06. Learn More on Jeff Kent's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Jeff Kent Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/5/2020	Sell	47,944	$78.94	$3,784,699.36	71,799
6/10/2020	Sell	2,785	$48.05	$133,819.25	65,994
6/1/2020	Sell	57,215	$49.94	$2,857,317.10
1/7/2020	Sell	3,545	$36.50	$129,392.50	121,988
8/5/2019	Sell	11,140	$23.84	$265,577.60	127,115
6/5/2019	Sell	3,620	$24.64	$89,196.80

Jeff Kent Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late